Author Archives: William Looney

Casing Cancer: ASCO Launches New Series on State of the Disease

Despite its importance as a vital indicator of overall population health status, cancer suffers from an information deficit – particularly when considered from a global perspective. The American Society of Clinical Oncology [ASCO], the lead professional group in this space, is now working to rectify at least part of the gap with the launch of […]
Posted in healthcare, leadership, Market Access, pricing, R&D, Regulatory, Safety, Strategy | Tagged , , , , , | Leave a comment

Pushing the Boundaries of MS Research: The Myelin Repair Foundation

R&D’s Double Header The Myelin Repair Foundation is more than just a policy precedent – it’s also emerging as the stimulus behind a future cure for MS. The decades-old movement for “patient power” is evolving in unexpected directions, as a few vanguard organizations explicitly abandon that vague agenda around “advocacy” for something more granular and […]
Posted in People, Strategy | Tagged , , , | 1 Comment

HBA's 2014 Woman of the Year: Broadening the Base

HBA’s 2014 Woman of the Year:  Broadening the Base To mark its 25th year in recognizing female leadership in the tough competitive ranks of biopharma, the Healthcare Businesswomen’s Association [HBA] is opting for a breakout triple play.  When the group convenes on May 1 in New York for its annual Woman of the Year [WOTY] […]
Posted in Events, healthcare, leadership, People | Tagged , , , , , | Leave a comment

From Cyprus to Cambridge: The Rise of Anna Protopapas, Millennium Takeda's New President

Takeda’s Oncology Taskmaster Millennium Takeda’s new president, Anna Protopapas, explains to Pharm exec’s William Looney the life choices that brought her from Cyprus to Cambridge—and a lead position in the hotly contested search to make cancer a treatable disease. PE: The ascent to the “c suite” is not exclusively the result of hard work. Culture, […]
Posted in Global, Strategy | Tagged , , , , | Leave a comment

Time for Russia to Get Serious about Biopharma

Back in 1980, the biotech industry did not exist. There was little difference between the means of production in Western markets and the socialist planned economies embodied by Russia – medicines, still a low-tech purchase, played a modest role in the delivery of health care in both sectors. What happened in the ensuing decades has […]
Posted in Biotech, Emerging Markets, Europe, Global, Strategy | Tagged , , , | 1 Comment
  • Categories

  • Meta